Hypobetalipoproteinemia: genetics, biochemistry, and clinical spectrum.

[1]  E. Levy,et al.  Guidelines for the diagnosis and management of chylomicron retention disease based on a review of the literature and the experience of two centers , 2010, Orphanet journal of rare diseases.

[2]  N. Seidah,et al.  The Influence of PCSK9 Polymorphisms on Serum Low-Density Lipoprotein Cholesterol and Risk of Atherosclerosis , 2010, Current atherosclerosis reports.

[3]  K. Schechtman,et al.  Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. , 2010, Gastroenterology.

[4]  D. Noto,et al.  Variable phenotypic expression of chylomicron retention disease in a kindred carrying a mutation of the Sara2 gene. , 2010, Metabolism: clinical and experimental.

[5]  Wen Xu,et al.  Combined MELD and blood lipid level in evaluating the prognosis of decompensated cirrhosis. , 2010, World journal of gastroenterology.

[6]  D. Figeys,et al.  Nonsynonymous Mutations within APOB in Human Familial Hypobetalipoproteinemia , 2009, The Journal of Biological Chemistry.

[7]  K. Berge,et al.  The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis , 2009, Journal of internal medicine.

[8]  A. Tuttolomondo,et al.  Familial hypobetalipoproteinemia due to apolipoprotein B R463W mutation causes intestinal fat accumulation and low postprandial lipemia. , 2009, Atherosclerosis.

[9]  P. Moulin,et al.  Identification of two novel mutations and long-term follow-up in abetalipoproteinemia: a report of four cases , 2009, European Journal of Pediatrics.

[10]  E. Levy,et al.  Chylomicron retention disease: a long term study of two cohorts. , 2009, Molecular genetics and metabolism.

[11]  Jonathan C. Cohen,et al.  PCSK9: a convertase that coordinates LDL catabolism Published, JLR Papers in Press, November 19, 2008. , 2009, Journal of Lipid Research.

[12]  A. Munnich,et al.  Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease , 2009, Human mutation.

[13]  Trond P. Leren,et al.  Mutation S462P in the PCSK9 gene reduces secretion of mutant PCSK9 without affecting the autocatalytic cleavage. , 2009, Atherosclerosis.

[14]  P. Tarugi,et al.  Identification of patients with abetalipoproteinemia and homozygous familial hypobetalipoproteinemia in Tunisia. , 2009, Clinica chimica acta; international journal of clinical chemistry.

[15]  D. Wattanasirichaigoon,et al.  Novel missense mutations of SAR1B gene in an infant with chylomicron retention disease. , 2009, Journal of pediatric gastroenterology and nutrition.

[16]  I. Cortella,et al.  Functional analysis of two novel splice site mutations of APOB gene in familial hypobetalipoproteinemia. , 2009, Molecular genetics and metabolism.

[17]  P. Laforêt,et al.  Anderson’s disease (chylomicron retention disease): a new mutation in the SARA2 gene associated with muscular and cardiac abnormalities , 2008, Clinical genetics.

[18]  E. Fisher,et al.  The many intersecting pathways underlying apolipoprotein B secretion and degradation , 2008, Trends in Endocrinology & Metabolism.

[19]  M. Bourbon,et al.  Variable phenotypic expression of homozygous familial hypobetalipoproteinaemia due to novel APOB gene mutations , 2008, Clinical Genetics.

[20]  Robert A Hegele,et al.  Abetalipoproteinemia: two case reports and literature review , 2008, Orphanet journal of rare diseases.

[21]  J. K. Laerdahl,et al.  Characterization of novel mutations in the catalytic domain of the PCSK9 gene , 2008, Journal of internal medicine.

[22]  R. Collins,et al.  Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths , 2007, The Lancet.

[23]  D. Noto,et al.  Molecular diagnosis of hypobetalipoproteinemia: an ENID review. , 2007, Atherosclerosis.

[24]  E. Boerwinkle,et al.  Sequence Variation in Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease Gene, Low LDL Cholesterol, and Cancer Incidence , 2007, Cancer Epidemiology Biomarkers & Prevention.

[25]  R. Hegele,et al.  Missense Mutations in APOB within the βα1 Domain of Human APOB-100 Result in Impaired Secretion of ApoB and ApoB-containing Lipoproteins in Familial Hypobetalipoproteinemia* , 2007, Journal of Biological Chemistry.

[26]  J. Horton,et al.  Catalytic Activity Is Not Required for Secreted PCSK9 to Reduce Low Density Lipoprotein Receptors in HepG2 Cells* , 2007, Journal of Biological Chemistry.

[27]  P. Flakoll,et al.  Defects in postabsorptive plasma homeostasis of fatty acids in sickle cell disease. , 2007, JPEN. Journal of parenteral and enteral nutrition.

[28]  Jonathan C. Cohen,et al.  Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation* , 2007, Journal of Biological Chemistry.

[29]  A. Soutar,et al.  Mechanisms of Disease: genetic causes of familial hypercholesterolemia , 2007, Nature Clinical Practice Cardiovascular Medicine.

[30]  D. Behar,et al.  Abetalipoproteinemia in Israel: evidence for a founder mutation in the Ashkenazi Jewish population and a contiguous gene deletion in an Arab patient. , 2007, Molecular genetics and metabolism.

[31]  K. Parhofer,et al.  Postprandial lipoprotein metabolism in familial hypobetalipoproteinemia. , 2007, The Journal of clinical endocrinology and metabolism.

[32]  D. Noto,et al.  A Novel Loss of Function Mutation of PCSK9 Gene in White Subjects With Low-Plasma Low-Density Lipoprotein Cholesterol , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[33]  Richard E Gregg,et al.  Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. , 2007, The New England journal of medicine.

[34]  A. Marais,et al.  Abstract 340: The C679X Mutation in PCSK9 is Present and Lowers Blood Cholesterol in a Southern African Population , 2006 .

[35]  D. Gantz,et al.  Defining lipid-interacting domains in the N-terminal region of apolipoprotein B. , 2006, Biochemistry.

[36]  Jonathan C. Cohen,et al.  Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. , 2006, American journal of human genetics.

[37]  Leiv Ose,et al.  Missense Mutations in the PCSK9 Gene Are Associated With Hypocholesterolemia and Possibly Increased Response to Statin Therapy , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[38]  T. Ranheim,et al.  Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. , 2006, Human molecular genetics.

[39]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[40]  Jonathan C. Cohen,et al.  Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Kastelein,et al.  Hepatic and Cardiovascular Consequences of Familial Hypobetalipoproteinemia , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[42]  M. Hussain,et al.  Intestinal lipoprotein assembly , 2005, Current opinion in lipidology.

[43]  S. Bertolini,et al.  Mutations in MTP gene in abeta- and hypobeta-lipoproteinemia. , 2005, Atherosclerosis.

[44]  D. Yablonskiy,et al.  Absence of fatty liver in familial hypobetalipoproteinemia linked to chromosome 3p21. , 2005, Metabolism: clinical and experimental.

[45]  R. Hammer,et al.  Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[46]  G. Schonfeld,et al.  Familial hypobetalipoproteinemia: genetics and metabolism , 2005, Cellular and Molecular Life Sciences.

[47]  J. Kastelein,et al.  High frequency of APOB gene mutations causing familial hypobetalipoproteinaemia in patients of Dutch and Spanish descent , 2005, Journal of Medical Genetics.

[48]  D. Rader,et al.  Complete Deficiency of the Low-Density Lipoprotein Receptor Is Associated With Increased Apolipoprotein B-100 Production , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[49]  W. Pandak,et al.  High-density lipoprotein cholesterol as an indicator of liver function and prognosis in noncholestatic cirrhotics. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[50]  Alexander Pertsemlidis,et al.  Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 , 2005, Nature Genetics.

[51]  F. V. van Bockxmeer,et al.  Monogenic Hypocholesterolaemic Lipid Disorders and Apolipoprotein B Metabolism , 2005, Critical reviews in clinical laboratory sciences.

[52]  F. V. van Bockxmeer,et al.  Lipid disorders and mutations in the APOB gene. , 2004, Clinical chemistry.

[53]  D. Yablonskiy,et al.  Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity. , 2004, Journal of lipid research.

[54]  C. Shoulders,et al.  The intracellular transport of chylomicrons requires the small GTPase, Sar1b , 2004, Current opinion in lipidology.

[55]  G. Gibbons,et al.  Synthesis and function of hepatic very-low-density lipoprotein. , 2004, Biochemical Society transactions.

[56]  Gang Li,et al.  Hepatic Secretion of Apob-100 Is Impaired in Hypobetalipoproteinemic Mice with an Apob-38.9-specifying Allele , 2022 .

[57]  E. Fisher,et al.  Apolipoprotein B100 Exit from the Endoplasmic Reticulum (ER) Is COPII-dependent, and Its Lipidation to Very Low Density Lipoprotein Occurs Post-ER* , 2003, Journal of Biological Chemistry.

[58]  G. S. Shelness,et al.  Identification of the Lipoprotein Initiating Domain of Apolipoprotein B* , 2003, Journal of Biological Chemistry.

[59]  De-Pei Liu,et al.  Regulation of human apolipoprotein B gene expression at multiple levels. , 2003, Experimental cell research.

[60]  G. Chang,et al.  CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. , 2003, Journal of lipid research.

[61]  D. Vanderjagt,et al.  Reduced cholesterol levels in African-American adults with sickle cell disease. , 2003, Journal of the National Medical Association.

[62]  Hetal N. Patel,et al.  Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders , 2003, Nature Genetics.

[63]  Gustav Schonfeld,et al.  Familial hypobetalipoproteinemia Published, JLR Papers in Press, March 16, 2003. DOI 10.1194/jlr.R300002-JLR200 , 2003, Journal of Lipid Research.

[64]  B. Miskie,et al.  A Novel Nontruncating APOB Gene Mutation, R463W, Causes Familial Hypobetalipoproteinemia* , 2003, The Journal of Biological Chemistry.

[65]  D. Yablonskiy,et al.  Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis. , 2003, Journal of lipid research.

[66]  D. Quilliot,et al.  Fatty acid abnormalities in chronic pancreatitis: effect of concomitant diabetes mellitus , 2003, European Journal of Clinical Nutrition.

[67]  H. Herscovitz,et al.  Nascent Lipidated Apolipoprotein B Is Transported to the Golgi as an Incompletely Folded Intermediate as Probed by Its Association with Network of Endoplasmic Reticulum Molecular Chaperones, GRP94, ERp72, BiP, Calreticulin, and Cyclophilin B* , 2003, The Journal of Biological Chemistry.

[68]  R. Hegele,et al.  Ileal adenocarcinoma in a mild phenotype of abetalipoproteinemia , 2003, Clinical genetics.

[69]  M. Hussain,et al.  Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly Published, JLR Papers in Press, September 16, 2002. DOI 10.1194/jlr.R200014-JLR200 , 2003, Journal of Lipid Research.

[70]  R. Duden.  ER-to-Golgi transport: COP I and COP II function (Review) , 2003, Molecular membrane biology.

[71]  H. Tamary,et al.  Hypocholesterolemia in children and adolescents with β-thalassemia intermedia , 2002 .

[72]  E. Fisher,et al.  Complexity in the Secretory Pathway: The Assembly and Secretion of Apolipoprotein B-containing Lipoproteins* , 2002, The Journal of Biological Chemistry.

[73]  K. Iseki,et al.  Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. , 2002, Kidney international.

[74]  L. Duntas.  Thyroid disease and lipids. , 2002, Thyroid : official journal of the American Thyroid Association.

[75]  A. Attie,et al.  Endoplasmic reticulum localization of the low density lipoprotein receptor mediates presecretory degradation of apolipoprotein B , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[76]  I. Cortella,et al.  Phenotypic expression of familial hypobetalipoproteinemia in three kindreds with mutations of apolipoprotein B gene. , 2001, Journal of lipid research.

[77]  J. Segrest,et al.  Structure of apolipoprotein B-100 in low density lipoproteins. , 2001, Journal of lipid research.

[78]  G. Marchesini,et al.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. , 2001, Diabetes.

[79]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[80]  C. Harris,et al.  Assembly of very low density lipoproteins in mouse liver: evidence of heterogeneity of particle density in the Golgi apparatus. , 2001, Journal of lipid research.

[81]  G. Schonfeld,et al.  A Targeted Apolipoprotein B-38.9-producing Mutation Causes Fatty Livers in Mice Due to the Reduced Ability of Apolipoprotein B-38.9 to Transport Triglycerides* , 2000, The Journal of Biological Chemistry.

[82]  D. Illingworth,et al.  Novel mutations in the microsomal triglyceride transfer protein gene causing abetalipoproteinemia. , 2000, Journal of lipid research.

[83]  S. Heath,et al.  A cholesterol-lowering gene maps to chromosome 13q. , 2000, American journal of human genetics.

[84]  J. Weber,et al.  Linkage of a gene for familial hypobetalipoproteinemia to chromosome 3p21.1-22. , 2000, American journal of human genetics.

[85]  R. Hegele,et al.  Microsomal triglyceride transfer protein (MTP) gene mutations in Canadian subjects with abetalipoproteinemia , 2000, Human mutation.

[86]  A. Attie,et al.  The role of the LDL receptor in apolipoprotein B secretion. , 2000, The Journal of clinical investigation.

[87]  G. Marchesini,et al.  Association of nonalcoholic fatty liver disease with insulin resistance. , 1999, The American journal of medicine.

[88]  G. Schonfeld,et al.  Decreased production rates of VLDL triglycerides and ApoB-100 in subjects heterozygous for familial hypobetalipoproteinemia. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[89]  J. Segrest,et al.  N-terminal domain of apolipoprotein B has structural homology to lipovitellin and microsomal triglyceride transfer protein: a "lipid pocket" model for self-assembly of apob-containing lipoprotein particles. , 1999, Journal of lipid research.

[90]  G. Schonfeld,et al.  Truncated apo B-70.5-containing lipoproteins bind to megalin but not the LDL receptor. , 1999, The Journal of clinical investigation.

[91]  John M. Hancock,et al.  The structure of vitellogenin provides a molecular model for the assembly and secretion of atherogenic lipoproteins. , 1999, Journal of molecular biology.

[92]  A. Lonardo,et al.  Familial Heterozygous Hypobetalipoproteinemia, Extrahepatic Primary Malignancy, and Hepatocellular Carcinoma , 1998, Digestive Diseases and Sciences.

[93]  P. Wilson,et al.  Frequency of ApoB and ApoE gene mutations as causes of hypobetalipoproteinemia in the framingham offspring population. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[94]  A. Lonardo,et al.  Heterozygous familial hypobetalipoproteinemia associated with fatty liver. , 1997, The American journal of gastroenterology.

[95]  T. Shoji,et al.  Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. , 1997, Atherosclerosis.

[96]  A. Lonardo,et al.  Fatty liver in heterozygous hypobetalipoproteinemia caused by a novel truncated form of apolipoprotein B. , 1996, Gastroenterology.

[97]  R. McLeod,et al.  Apolipoprotein B Sequence Requirements for Hepatic Very Low Density Lipoprotein Assembly , 1996, The Journal of Biological Chemistry.

[98]  P. Talmud,et al.  The Amino Terminus of Apolipoprotein B Is Necessary but Not Sufficient for Microsomal Triglyceride Transfer Protein Responsiveness (*) , 1996, The Journal of Biological Chemistry.

[99]  C. Aguilar-Salinas,et al.  Positive linear correlation between the length of truncated apolipoprotein B and its secretion rate: in vivo studies in human apoB-89, apoB-75, apoB-54.8, and apoB-31 heterozygotes. , 1996, Journal of lipid research.

[100]  M. Fox,et al.  Mutations of the microsomal triglyceride-transfer-protein gene in abetalipoproteinemia. , 1995, American journal of human genetics.

[101]  B. Angelin,et al.  Studies on lipoprotein metabolism in a family with jejunal chylomicron retention , 1995, European journal of clinical investigation.

[102]  S. Yusuf,et al.  Report of the Conference on Low Blood Cholesterol: Mortality Associations , 1992, Circulation.

[103]  M. Law,et al.  Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies , 1991, Cancer Causes & Control.

[104]  H. Tyroler,et al.  Changes in plasma lipid and lipoprotein cholesterol and weight prior to the diagnosis of cancer. , 1991, Cancer research.

[105]  E. Wynder,et al.  Diet and serum lipids in vegan vegetarians: a model for risk reduction. , 1991, Journal of the American Dietetic Association.

[106]  J. Carstensen,et al.  Cancer incidence and cancer mortality in relation to serum cholesterol. , 1989, Journal of the National Cancer Institute.

[107]  I. Sternlieb,et al.  Hepatic peroxisomal abnormalities in abetalipoproteinemia. , 1989, Gastroenterology.

[108]  S. Pettinato,et al.  Plasma lipids in beta-thalassemia minor. , 1989, Atherosclerosis.

[109]  E. Levy,et al.  Malabsorption, hypocholesterolemia, and fat-filled enterocytes with increased intestinal apoprotein B. Chylomicron retention disease. , 1987, Gastroenterology.

[110]  G. Gahrton,et al.  HYPOCHOLESTEROLAEMIA IN MALIGNANCY DUE TO ELEVATED LOW-DENSITY-LIPOPROTEIN-RECEPTOR ACTIVITY IN TUMOUR CELLS: EVIDENCE FROM STUDIES IN PATIENTS WITH LEUKAEMIA , 1985, The Lancet.

[111]  M. Heimberg,et al.  Plasma lipoproteins and regulation of hepatic metabolism of fatty acids in altered thyroid states. , 1985, Endocrine reviews.

[112]  E. Oldfield,et al.  Abetalipoproteinemia and metastatic spinal cord glioblastoma. , 1984, Archives of neurology.

[113]  M. Shipley,et al.  PLASMA LIPIDS AND MORTALITY: A SOURCE OF ERROR , 1980, The Lancet.

[114]  N. Mcintyre.  Plasma lipids and lipoproteins in liver disease. , 1978, Gut.

[115]  T. Kanehisa,et al.  Hypobetalipoproteinemia with abnormal prebetalipoprotein , 1977, Journal of the Neurological Sciences.

[116]  M. Westerman.  Hypocholesterolaemia and Anaemia , 1975, British journal of haematology.

[117]  F. Sacks,et al.  Plasma lipids and lipoproteins in vegetarians and controls. , 1975, The New England journal of medicine.

[118]  G. Stamatoyannopoulos,et al.  SERUM-CHOLESTEROL AND THALASSÆMIA TRAIT , 1963 .

[119]  G. Stamatoyannopoulos,et al.  Serum-cholesterol and thalassemia trait. , 1963, Lancet.

[120]  E. Nash,et al.  Prevalence of dyslipidemia in adults with cystic fibrosis. , 2010, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[121]  Z. Yao,et al.  ReviewRecent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion , 2010 .

[122]  E. Levy,et al.  Anderson or chylomicron retention disease: molecular impact of five mutations in the SAR1B gene on the structure and the functionality of Sar1b protein. , 2008, Molecular genetics and metabolism.

[123]  Y. Kokubo,et al.  Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population. , 2008, Atherosclerosis.

[124]  Eric Boerwinkle,et al.  Sequence Variations in PCSK 9 , Low LDL , and Protection against Coronary Heart Disease , 2006 .

[125]  Gustav Schonfeld,et al.  Genetic variants of ApoE account for variability of plasma low-density lipoprotein and apolipoprotein B levels in FHBL. , 2005, Atherosclerosis.

[126]  L. Aggerbeck,et al.  The role of the microsomal triglygeride transfer protein in abetalipoproteinemia. , 2000, Annual review of nutrition.

[127]  C. Aguilar-Salinas,et al.  Apoprotein B-100 production is decreased in subjects heterozygous for truncations of apoprotein B. , 1995, Arteriosclerosis, thrombosis, and vascular biology.